Testopel (Testosterone) Patent Expiration, LOE Window & CMS Spending
Testopel (Testosterone) by Endo Pharmaceuticals: Off-Patent Genericized (AB Competition), 11 AB generics, $2.0M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Endo Pharmaceuticals |
| FDA Application & Pathway | Reconciled (UNLINKED) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 11 |
| 2024 CMS Total Public Spend | $2.0M |
| 2024 Medicare Part D Spend | $1.3M |
| 2024 Medicaid Spend | $702K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |